2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 291-292
Technology and Procedures, Omics Technologies, Bioinformatics, Gene Editing, Profiling, Treatment Considerations, Biological Therapies, Gene Therapy, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Metabolic Disorders, Research, Fundamental Science, Translational Research, Study Population, Animal Model
PAPER

327 Inherited anemia due to a novel inter-zinc finger GATA1 mutation: Mechanistic and therapeutic implications

Nishi Arun Harwani, MBBS, Sukhmanjit Kaur, PhD2, Saicharan Akula, PhD3, Nana Liu, PhD4, Priyanka Singh, PhD5, Dewan Shreshtha, PhD6, Catherine Nelson, DO7, Sonia Goozzee8, Lei Han, PhD9, Sara Lewis, MS GC10, Michelle Boals, NP11, William Beau Mitchell, MD12, Marcin W Wlodarski, MD, PhD13, Merlin Crossley, PhD14, Joel Mackay, PhD15, Mitchell Weiss, MD, PhD16, Senthil Bhoopalan, MD PhD17
1 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
2 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
3 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
4 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
5 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
6 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
7 Sanford Children's Hospital, Sioux Falls, South Dakota, United States
8 University of New South Wales, Sydney, Australia
9 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
10 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
11 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
12 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
13 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
14 University of New South Wales, Sydney, Australia
15 University of Sydney, Sydney, Australia
16 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
17 St. Jude Children's Research Hospital, Memphis, Tennessee, United States

GATA1 is a master transcription factor essential for erythropoiesis and megakaryopoiesis. The GATA1 protein contains a transactivation domain and two zinc fingers (zf). The N-terminal zf is responsible for interaction with transcriptional co-factors such as FOG1 and LMO2, and stabilization of DNA binding. The C-terminal zf is primarily responsible for the binding of GATA1 to the consensus WGATAR sequence. Different germline mutations in the X-linked GATA1 gene are associated with distinct phenotypes and disease labels, including Diamond-Blackfan anemia, dyserythropoietic anemia, hemolytic anemia, thrombocytopenia, and, rarely, neutropenia, with variable severity. We recently identified a novel GATA1 variant (c.757C>T, p.R253W) with an amino acid substitution in the inter-zinc-finger linker region in a patient with transfusion-dependent anemia. The functional consequences of mutations in this region remain undefined. Here, we investigate the cellular and molecular consequences of GATA1 R253W and use patient-derived induced pluripotent stem cells (iPSCs) to demonstrate the feasibility of base editing to correct the hematopoietic defect.  

The index patient is a male who has required frequent packed red blood cell (pRBC) transfusions since age 3 years. He was noted to have macrocytic anemia, reticulocytosis, decreased serum haptoglobin, and thrombocytosis. Peripheral blood smear showed anisocytosis, multilobed nucleated RBCs, and giant platelets, some lacking an actin ring. Bone marrow examination showed a normocellular marrow with dysplastic erythrocytes and megakaryocytic hyperplasia. Gene panel testing identified a GATA1 c.757C>T (p.R253W) variant. The proband’s older brother had pRBC transfusion-dependent anemia and harbored the same variant. The patient’s mother and older sister are unaffected heterozygous carriers. The R253W substitution occurs within the inter-Zf region and is predicted to be pathogenic because it: a) is not present in 141,456 healthy subjects (GnomAD database, version 2.1.1); b) tracks with symptomatic male family members; and c) is predicted to be deleterious (Rare Exome Variant Ensemble Learner [REVEL] score 0.85).  

We generated iPSCs from the index patient’s peripheral blood mononuclear cells, and differentiated them into definitive iPSC-derived hematopoietic stem cells (iHSCs) using a recently published protocol (Ng et al, Nat Biotech, 2025), followed by vitro erythroid differentiation. Compared to healthy control iHSCs, GATA1R253W iHSCs showed an approximately 5-fold decrease in cell counts on day 14 of erythroid culture (P<0.05) with a 77% reduction in the percentage of CD71-CD235a+ erythroblasts (11.4% vs 48%, P<0.05). Treatment of the GATA1R253W iHSCs with an adenine base editor and localizing guide RNA corrected approximately 90% of the mutated alleles. Upon erythroid differentiation, the corrected iHSCs exhibited a 4-fold expansion compared to uncorrected mutant cells P<0.05), and a 3-fold increase in the fraction of CD71-CD235a+ erythroblasts (36.50% vs 11.4%, P<0.05). Transcriptome analysis of mutant iHSC-derived erythroblasts revealed marked suppression of several key GATA1 target genes (SLCA1, GYPE, GYPA, TAL1, KLF1, HBM, HBZ, HBA1/2) in mutant cells compared with normal donor control and edited cells, reflecting impaired GATA1 activity. Competitive electrophoretic mobility shift assay (EMSA) indicated that R253W GATA1 has an accelerated off-rate from reverse palindromic, tandem, and single GATA sites compared to the wild-type protein, suggesting that the mutant protein may exhibit impaired binding to a subset of GATA1 target sites in vivo, with resultant dyserythropoietic anemia. Additional functional studies, including CUT&RUN to analyze binding of the mutant protein to chromatin in erythroid precursors, are ongoing. 

In summary, we identified a novel germline GATA1 inter-Zf mutation that causes dyserythropoietic anemia and thrombocytosis. We used patient-derived iPSCs to investigate the molecular mechanism underlying the hematopoietic defect and to assess the feasibility of therapeutic adenine base editing. Specifically, we show that the GATA1 R253W mutation disrupts zinc finger binding to key target genes and that the resulting erythroid transcriptional network failure is rescued by base editing. 

Nishi Arun Harwani, MBBS: No relevant conflicts of interest to declare.